A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Completed
Observational Study
Carcinoma, Non-Small-Cell Lung
Anaplastic Lymphoma Kinase
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 271
- Sponsor
- Takeda · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. With ALK-positive advanced or metastatic NSCLC.
2. Who initiate brigatinib for the first time.
Exclusion Criteria:
1. Treated with brigatinib outside of the locally approved label in Korea.
2. Whom brigatinib is contraindicated as per product label.
3. Participating in othe…
Contacts
No contact information available.